François Meyer
Keine laufenden Positionen mehr
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Rudy L. Rodriguez | M | 72 | 20 Jahre | |
| Paula Soteropoulos | F | 56 | 11 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Sander J. van Deventer | M | 69 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 15 Jahre |
| Philip Astley-Sparke | M | 51 | 8 Jahre | |
| Joseph Feczko | M | 75 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 6 Jahre |
| David Schaffer | M | 53 | 6 Jahre | |
| Ferdinand Verdonck | M | 81 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 4 Jahre |
| Hugo Slootweg | M | 53 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 8 Jahre |
| Jan A. Bielinski | M | 70 |
University of Zurich
| 6 Jahre |
| Philip Pisanelli | M | 76 | - | |
| Philippe van Holle | M | 69 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 15 Jahre |
| Michel Liès | M | 70 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Ernst A. Häberli | M | 75 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Max E. Link | M | 84 |
Sandoz Pharmaceuticals AG
 Sandoz Pharmaceuticals AG BiotechnologyHealth Technology Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland. | 22 Jahre |
| Harald Petry | M | 65 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 10 Jahre |
| Peter Krebser | M | 72 |
Sandoz Pharmaceuticals AG
Sandoz Pharmaceuticals AG BiotechnologyHealth Technology Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland.
Swiss Federal Institute of Technology
| 23 Jahre |
| Urs E. Kohler | M | 79 |
University of Zurich
| 6 Jahre |
| Juerg Winter | M | - |
Swiss Federal Institute of Technology
| 8 Jahre |
| Ernst-Ludwig Winnacker | M | 82 |
Swiss Federal Institute of Technology
| 7 Jahre |
| Jean Bizzari | M | 69 |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | 4 Jahre |
| Arnold Vroege | M | - |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 6 Jahre |
| Jean-Pierre Labroue | M | 60 |
Rhone Poulenc Rorer
Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | 3 Jahre |
| Peter Schmalz | M | 81 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Thomas Frank Daetwyler | M | 69 |
University of Zurich
| 4 Jahre |
| Hans Preusting | M | 62 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 7 Jahre |
| Monique Marelis | F | - |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 5 Jahre |
| Michel Perraudin | M | 78 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Alexander Bleibler | M | 70 |
University of Zurich
| 4 Jahre |
| Urs Mäder | M | 68 |
University of Zurich
| 4 Jahre |
| Markus Isenrich | M | 71 |
University of Zurich
| 3 Jahre |
| Periclès–Paul P. Petalas | M | 81 |
Swiss Federal Institute of Technology
| 3 Jahre |
| Beat Bernet | M | 69 |
University of Zurich
| 3 Jahre |
| Carlos R. Camozzi | M | 71 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 2 Jahre |
| Hans Rigendinger | M | 79 |
Swiss Federal Institute of Technology
| 1 Jahre |
| Markus Schnurrenberger | M | - |
University of Zurich
| 5 Jahre |
| Schlumpf Widmer-Schlumpf | F | 68 |
University of Zurich
| 4 Jahre |
| Janine Cossy | F | - |
Centre National de la Recherche Scientifique
 Centre National de la Recherche Scientifique General GovernmentGovernment Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France. | 21 Jahre |
| Mauro dell'Ambrogio | M | - |
University of Zurich
| 3 Jahre |
| Michael P. Cooke | M | 62 |
Systemix, Inc.
 Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | 6 Jahre |
| Erich Bohli | M | 74 |
University of Zurich
| 3 Jahre |
| Deya Corzo | M | 57 | 3 Jahre | |
| Rudolf Heinrich Escher | M | 67 |
University of Zurich
| 4 Jahre |
| Jacques de Saussure | M | - |
Swiss Federal Institute of Technology
| 4 Jahre |
| Efrat Konforty | F | - | - | |
| Ulrich Schluer | M | 80 |
University of Zurich
| 3 Jahre |
| Claudia Meyer | M | - |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | - |
| Ursus Zinsli | M | - |
University of Zurich
| 4 Jahre |
| Ioannis Panagiotis Votsaridis | M | 73 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Patrizia Holenstein | M | 67 |
University of Zurich
| 4 Jahre |
| Patrick K. Oesch | M | 66 |
University of Zurich
| 3 Jahre |
| David Gearing | M | 62 |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | 1 Jahre |
| Reinold Geiger | M | 76 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Nadia Badri | M | - |
Rhone Poulenc Rorer
Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | 4 Jahre |
| Marc Bär | M | - |
University of Zurich
| 4 Jahre |
| Hans-Rudolf Spiess | M | 75 |
Swiss Federal Institute of Technology
| 3 Jahre |
| Claude Martin | M | 79 |
University of Zurich
| 3 Jahre |
| Hans-Christian Rohde | M | 67 | - | |
| Markus K. Christen | M | - |
University of Zurich
| 3 Jahre |
| Peter Leupp | M | 72 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Joseph DeRose | M | 68 |
BASF Performance Products Ltd. (United Kingdom)
 BASF Performance Products Ltd. (United Kingdom) Chemicals: SpecialtyProcess Industries Basf Performance Products Ltd. manufactures chemical products. It offers dyes and pigments, plastics, and other inorganic basic chemicals. The company was founded on September 12, 1996 and is headquartered in Cheadle, the United Kingdom. | 19 Jahre |
| Christoph Schmid | M | 70 |
University of Zurich
| 3 Jahre |
| Edwin de Graaf | M | - | - | |
| Thomas H. Eckelmann | M | 73 |
University of Zurich
| 4 Jahre |
| Rolf Soiron | M | 79 |
Sandoz Pharmaceuticals AG
Sandoz Pharmaceuticals AG BiotechnologyHealth Technology Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland. | 1 Jahre |
| Peter Anton Joseph Kurer | M | 75 |
University of Zurich
| 3 Jahre |
| Thomas Rudolf Eichler | M | 69 |
University of Zurich
| 3 Jahre |
| Piers John Morgan | M | 57 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 4 Jahre |
| Thomas Callaway | M | - |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | 2 Jahre |
| Stewart Craig | M | 63 |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | 2 Jahre |
| Hiroshi Tomono | M | 78 |
Swiss Federal Institute of Technology
| 3 Jahre |
| Pierre de Weck | M | 73 |
Swiss Federal Institute of Technology
| 1 Jahre |
| Tis Prager | M | 76 |
University of Zurich
| 3 Jahre |
| Gerhard Mayr | M | 78 |
Swiss Federal Institute of Technology
| 1 Jahre |
| Walter Blättler | M | 75 |
Swiss Federal Institute of Technology
| 1 Jahre |
| Paul Herrling | M | 78 |
University of Zurich
| 3 Jahre |
| Steven Holtzman | M | 70 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | - |
| Christian Meyer | M | 56 | 4 Jahre | |
| Philippe Weigerstorfer | M | 64 |
Sandoz Pharmaceuticals AG
Sandoz Pharmaceuticals AG BiotechnologyHealth Technology Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland. | - |
| Felix Bärlocher | M | 76 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Bernhard M. Hammer | M | 73 |
University of Zurich
| 3 Jahre |
| Paul Schneider | M | 69 |
University of Zurich
| 1 Jahre |
| Alexander Jakob Boris Zehnder | M | - |
Swiss Federal Institute of Technology
| 1 Jahre |
| David Chaplin | M | 68 |
Rhone Poulenc Rorer
Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | 1 Jahre |
| Thomas Wetzel | M | 67 |
University of Zurich
| 3 Jahre |
| Ernst Brugger | M | 77 |
University of Zurich
| 3 Jahre |
| Andrea Thaddaus Vasella | M | 81 |
Swiss Federal Institute of Technology
| 3 Jahre |
| Ralph Max Büchi | M | 67 |
University of Zurich
| 4 Jahre |
| Hans Baumgartner | M | 70 |
University of Zurich
| 3 Jahre |
| Karl Hofstetter | M | 68 |
University of Zurich
| 3 Jahre |
| Krzysztof Opawski | M | 74 |
University of Zurich
| 1 Jahre |
| Rudolf W. Fischer | M | 72 |
University of Zurich
| 3 Jahre |
| Antonio Matteo Taormina | M | 76 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Niklaus Peter Nüesch | M | 70 |
Swiss Federal Institute of Technology
| 7 Jahre |
| Heinrich Andreas Baumann | M | 72 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Guy Wais | M | 82 |
Swiss Federal Institute of Technology
| 4 Jahre |
| Urs Wehinger | M | 79 |
University of Zurich
| 3 Jahre |
| Martin Leuthold | M | 72 |
University of Zurich
| 4 Jahre |
| Rudolf Wehrli | M | 75 |
University of Zurich
| 2 Jahre |
| Rodolfo Straub | M | - |
University of Zurich
| 3 Jahre |
| Duccio Alberti | M | 72 |
Swiss Federal Institute of Technology
| 3 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Schweiz | 42 | 42,00% |
| Deutschland | 26 | 26,00% |
| Niederlande | 21 | 21,00% |
| Vereinigte Staaten | 7 | 7,00% |
| Frankreich | 4 | 4,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- François Meyer
- Persönliches Netzwerk